Profile: Allergan Inc (AGN)

AGN on New York Consolidated

166.43USD
11 Jul 2014
Price Change (% chg)

$0.83 (+0.50%)
Prev Close
$165.60
Open
$163.01
Day's High
$166.98
Day's Low
$163.01
Volume
953,461
Avg. Vol
4,403,179
52-wk High
$174.49
52-wk Low
$86.95

Search Stocks

Allergan, Inc., incorporated on April 14,1977, is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company’s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologic products and the medical devices segment, which produces a range of medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products, and facial aesthetics products. In April 2014, TauTona Group’s subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc.

The Company’s research and development activities are focused on products and technologies related to the many specialty areas in which it operates as well as new specialty areas where there are unmet medical . The Company discovers, develops and commercializes a diverse range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries around the world.

Specialty Pharmaceuticals Segment

The Company develops, manufactures and markets a range of prescription and non-prescription products designed to treat diseases and disorders of the eye, including dry eye, glaucoma, inflammation, infection, allergy and retinal disease. Restasis (cyclosporine ophthalmic emulsion) is an eye care product, is the prescription ophthalmic pharmaceutical by sales value in the United States and is the first, and the only, prescription eye drop to help increase tear production in cases where tear production may be reduced by inflammation due to chronic dry eye. Its artificial tears products, including Refresh and Optive lubricant eye drops, treat dry eye symptoms including irritation and dryness due to pollution, computer use, aging and other causes.

The Company’s Lumigan(bimatoprost ophthalmic solution) product line is its selling eye care product line. Lumigan is a topical treatment indicated for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension. Ganfortt (bimatoprost/timolol maleate ophthalmic solution) is a bimatoprost and timolol maleate combination designed to treat glaucoma and ocular hypertension in patients who are not responsive to treatment with only one medication. Combigan(brimonidine tartrate/timolol maleate ophthalmic solution) 0is a brimonidine and timolol combination designed to treat ocular hypertension in glaucoma patients who are not responsive to treatment with only one medication or need additional therapy. Acuvail (ketorolac tromethamine ophthalmic solution) is a nonsteroidal, anti-inflammatory indicated for the treatment of ocular pain and inflammation following cataract surgery. Zymaxid(gatifloxacin ophthalmic solution) is an anti-infective product indicated for the treatment of bacterial conjunctivitis. Lastacaft (alcaftadine ophthalmic solution) is a topical allergy medication for the prevention and treatment of itching associated with allergic conjunctivitis.

The Company’s Elestat (epinastine HCL ophthalmic solution) is used for the prevention of itching associated with allergic conjunctivitis. Ozurdex (dexamethasone intravitreal implant) 0.7 milligram is a novel bioerodable formulation of dexamethasone in Novadur sustained-release drug delivery system that can be used to locally and directly administer medications to the retina. The Company’s Botox (onabotulinumtoxinA) is for the treatment of strabismus and blepharospasm, two eye muscle disorders, making it the first botulinum toxin type A product approved in the world. Since its first approval, Botox has been approved by regulatory authorities worldwide as a treatment for approximately 26 indications in approximately 88 countries. Botox have been well-established in approximately 65 randomized, placebo-controlled clinical trials and in approximately 15,000 patients treated with Botox and Botox Cosmetic in Allergan's clinical trials. Botox is used therapeutically for the treatment of certain neuromuscular disorders which are characterized by involuntary muscle contractions or spasms, as well for axillary hyperhydrosis and the prophylactic treatment of headaches in adults with chronic migraine.

The Company’s skin care products focus on the acne, psoriasis, physician-dispensed skin care and eyelash growth markets, particularly in the United States and Canada. Aczone (dapsone) gel is is indicated for the treatment of acne vulgaris in patients age 12 and older. Tazorac (tazarotene) gel is for the treatment of mild to moderate acne and stable plaque psoriasis, a chronic skin disease characterized by dry red patches. It also markets a cream formulation of Tazorac in the United States for the topical treatment of acne and for the treatment of plaque psoriasis. Vivit is an advanced anti-aging skin care line that uses GLX Technology, creating a specialized blend of glycolic acid and natural antioxidants. Latisse (bimatoprost ophthalmic solution) is the first, and the only, FDA-approved prescription treatment for insufficient or inadequate eyelashes. The SkinMedica family of products includes a variety of physician-dispensed, non-prescription aesthetic skin care products, including Lytera, TNS (Tissue Nutrient Solution) and Vaniqa. Lytera is a non-prescription, non-hydroquinone skin brightening product that minimizes the appearance of skin discoloration and dark spots. The TNS anti-aging non-prescription product line contains NouriCel, a patented biotechnology derived enriched nutrient solution, and includes cleansing, toning, moisturizing, sun protection, acne, visible redness, lightening products and peels. Vaniqa (eflornithine HCl) is a topical prescription cream used to reduce the growth of facial hair in women. Sanctura XR is its once-daily anticholinergic for the treatment of overactive bladder, or OAB.

The Company competes with Alcon Laboratories, Inc./Novartis AG, Abbott Laboratories, Bausch & Lomb, Inc., Genentech/Hoffman La Roche AG, Ista Pharmaceuticals, Inc., Merck & Co./Inspire Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Seiyaku, Excela PharmaSci, Inc., Apotex Inc., Barr Laboratories, Inc., Sandoz, Inc., Alcon Research, Ltd., Watson Laboratories, Inc., Lupin Limited, High-Tech Pharmacal Co., Inc., Johnson & Johnson, Medy-Tox Inc., Galderma, Medicis Pharmaceutical Corporation (Medicis), GSK, Merck & Co., Inc., Obagi Medical Products, Inc., L'Oreal Group, SkinMedica, Inc., Valeant Pharmaceuticals International, Watson Pharmaceuticals, Inc., Warner Chilcott PLC, Astellas Pharma US, Inc. and Ipsen Ltd. (Ipsen).

Medical Devices Segment

The Company’s silicone gel and saline breast implants, consisting of a variety of shapes, sizes and textures, have been available to women and are sold in approximately 75 countries for breast augmentation, revision and reconstructive surgery. Its breast implants consist of a silicone elastomer shell filled with either a saline solution or silicone gel with varying degrees of cohesivity. This shell can consist of either a smooth or textured surface. It markets its breast implants and tissue expanders under the trade names Natrelle, Inspira, BRST and CUI and the trademarks BioCell, MicroCell and BioDimensional. It markets over 1,000 breast implant product variations worldwide to meet its patients' preferences and needs. The Natrelle 410 shaped silicone breast implants, which are designed to mimic the slope of the breast to deliver a subtle, non-augmented look. It also sells a line of tissue expanders primarily for breast reconstruction and also as an aid to skin grafting to cover burn scars and correct birth defects.

The Lap-Band System is designed to provide minimally invasive long-term treatment of severe obesity and is used as an alternative to more invasive procedures such as gastric bypass or sleeve gastrectomy. The Lap-Band System is an adjustable silicone band that is laparoscopically placed around the upper part of the stomach through a small incision, creating a small pouch at the top of the stomach, which slows the passage of food and creates a sensation of fullness. The Lap-Band AP System has 360-degree Omniform technology, which is designed to evenly distribute pressure throughout the band's adjustment range. hypertension. The Lap-Band System was previously only approved for adults with a BMI of at least 35 and at least one comorbid condition as well as adults with a BMI of at least 40.

The Orbera Intragastric Balloon System is a non-surgical alternative for the treatment of overweight and obese adults that is approved for sale outside the United States in over 60 countries. The Orbera System includes a silicone elastomer balloon that is filled with saline after transoral insertion into the patient's stomach to reduce stomach capacity and create an earlier sensation of fullness. The Orbera System is removed endoscopically within six months after placement.

The Company’s Juvderm dermal filler family of products are designed to improve facial appearance by smoothing wrinkles and folds using itsproprietary Hylacross and Vycross technology. This technology enables the delivery of a homogeneous gel-based hyaluronic acid. Outside the United States, it market various formulations of Juvederm, including Juvderm Voluma for wrinkle and fold augmentation as well as volume deficits. The Juvederm dermal filler family of products are sold in approximately 89 countries, including world markets.

The Company competes with Mentor, Silimed, Eurosilicone, Nagor, Polytech, Johnson & Johnson, Helioscopie SA, Medical Innovation Development SAS, Cousin Biotech, Bariatric Solns, Spatz FGIA, Endalis, Medicis Pharmaceutical Corporation (Medicis), Bioform, Valeant Pharmaceuticals, Inc. (Valeant), Merz, Q-Med, Teoxane, Anteis and Agency for Medical Innovation.

Company Address

Allergan Inc

2525 Dupont Drive
IRVINE   CA   92612
P: +1714.2464500
F: +1714.2466987

Search Stocks